Skip to main content
Bohn Stafleu van Loghum
ZOEKEN
MENU 1 2 3 4
main-content
Top

Tip

Swipe om te navigeren naar een ander hoofdstuk

Gepubliceerd in:
Slaap: een algemene inleiding hoofdstuk lezen eerste hoofdstuk lezen

2021 | OriginalPaper | Hoofdstuk

19. Psychofarmaca en de behandeling van slaapstoornissen

Auteurs : drs. Maaike van Veen, dr. Jeanine Kamphuis, dr. Rixt Riemersma-van der Lek

Gepubliceerd in: Slaapstoornissen in de psychiatrie

Uitgeverij: Bohn Stafleu van Loghum

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Samenvatting

Niet-medicamenteuze interventies zijn bij slaapstoornissen van groot belang en vaak de primaire behandelstap. Toch wordt om diverse redenen frequent gekozen voor inzet van medicatie; bijvoorbeeld door onvoldoende effect van de gekozen interventies of de noodzaak zo snel mogelijk slaapverbetering te induceren. Dan is kennis over de werking van en evidentie voor het gebruiken van diverse middelen voor het verbeteren van slaap noodzakelijk. Geregistreerde slaapmiddelen, zoals benzodiazepinen, zijn effectief op de korte termijn, maar kennen aanzienlijke nadelen. Off-labelgebruik van diverse psychofarmaca, met als doel slaapverbetering, is voor een aantal middelen goed verdedigbaar gezien de effecten op de slaaparchitectuur, maar ook deze hebben alle hun eigen (bijwerkingen)profiel. De invloed op de rijvaardigheid moet standaard besproken worden. Indien langdurig gebruikte slaapmiddelen afgebouwd moeten worden, zijn belangrijke uitgangspunten dit langzaam te doen en intensief te begeleiden. De voorschrijver van psychiatrische medicatie dient zich verder bewust te zijn van slaapverstorende bijwerkingen van diverse psychofarmaca.
vorige hoofdstuk Niet-medicamenteuze behandeling van slaapstoornissen in de psychiatrie
volgende hoofdstuk Slaapproblemen bij kinderen en jeugdigen
Literatuur
Anderson, S. L., & Vande Griend, J. P. (2014). Quetiapine for insomnia: A review of the literature. American Journal of Health System Pharmacy, 71(5), 394–402.
Aringhieri, S., Kolachalam, S., Gerace, C., et al. (2017). Clozapine as the most efficacious antipsychotic for activating ERK 1/2 kinases: Role of 5-HT2A receptor agonism. European Neuropsychopharmacology, 27(4), 383–398. PubMedCrossRef
Atkin, T., Comai, S., & Gobbi, G. (2018). Drugs for insomnia beyond benzodiazepines: Pharmacology, clinical applications, and discovery. Pharmacological Reviews, 70(2), 197–245. PubMedCrossRef
Ayabe, N., Okajima, I., Nakajima, S., et al. (2018). Effectiveness of cognitive behavioral therapy for pharmacotherapy-resistant chronic insomnia: A multi-center randomized controlled trial in Japan. Sleep Medicine, 50, 105–112. PubMedCrossRef
Baandrup, L, Ebdrup, B. H., Rasmussen, J. O., Lindschou, J., Gluud, C., & Glenthoj, B. Y. (2018). Pharmacological interventions for benzodiazepine discontinuation in chronic benzodiazepine users. The Cochrane Database of Systematic Reviews, 3, CD011481.
Ballester, P., Martinez, M. J., Inda, Md. M., et al. (2019). Evaluation of agomelatine for the treatment of sleep problems in adults with autism spectrum disorder and co-morbid intellectual disability. Journal of Psychopharmacology, 33(11), 1395–1406.
Barret, J. R., Tracy, D. K., & Giaroli, G. (2013). To sleep or not to sleep: A systematic review of the literature of pharmacological treatments of insomnia in children and adolescents with attention-deficit/hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 23(10), 640–647. CrossRef
Bastien, C. H., LeBlanc, M., Carrier, J., & Morin, C. M. (2003). Sleep EEG power spectra, insomnia, and chronic use of benzodiazepines. Sleep, 26(3), 313–317. PubMedCrossRef
Bayard, M., Bailey, B., Acharya, D., Ambreen, F., Duggal, S., Kaur, T., et al. (2011). Bupropion and restless legs syndrome: a randomized controlled trial. Journal of the American Board of Family Medicine, 24(4), 422–428. PubMedCrossRef
Beaulieu-Bonneau, S., Ivers, H., Guay, B., Morin, C. M. (2017). Long-term maintenance of therapeutic gains associated with cognitive-behavioral therapy for insomnia delivered alone or combined with zolpidem. Sleep, 1, 40(3).
Berlant, J., & Van Kammen, D. P. (2002). Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: A preliminary report. Journal of Clinical Psychiatry, 63, 15–20. PubMedCrossRef
Biard, K., Douglass, A. B., & De Koninck, J. (2015). The effects of galantamine and buspirone on sleep structure: Implications for understanding sleep abnormalities in major depression. Journal of Psychopharmacology, 29(10), 1106–1111. PubMedCrossRef
Brecht, S., Kajdasz, D., Ball, S., & Thase, M. E. (2008). Clinical impact of duloxetine treatment on sleep in patients with major depressive disorder. International Clinical Psychopharmacology, 23, 317–324. PubMedCrossRef
Brower, K. J., Myra Kim, H., Strobbe, S., Karam-Hage, M. A., Consens, F., & Zucker, R. A. (2008). A randomized double-blind pilot trial of gabapentin versus placebo to treat alcohol dependence and comorbid insomnia. Alcoholism, Clinical and Experimental Research, 32(8), 1429–1438. PubMedPubMedCentralCrossRef
Brown, R. E., Basheer, R., McKenna, J. T., Strecker, R. E., & McCarley, R. W. (2012). Control of sleep and wakefulness. Physiological Reviews, 92(3), 1087–1187. PubMedCrossRef
Carley, D. W., Olapade, C., Ruigt, G. S., & Radulovacki, M. (2007). Efficacy of mirtazapine in obstructive sleep apnea. Sleep, 30(1), 35–41. PubMedCrossRef
Carvalho, L., Gorenstein, C., Moreno, R., Pariante, C., & Markus, R. (2009). Effect of antidepressants on melatonin metabolite in depressed patients. Journal of Psychopharmacology, 23(3), 315–321. PubMedCrossRef
Cohrs, S. (2008). Sleep disturbances in patients with schizophrenia: impact and effect of antipsychotics. CNS Drugs, 22(11), 939–962. PubMedCrossRef
Cohrs, S., Rodenbeck, A., Guan, Z., Pohlmann, K., Jordan, W., Meier, A., et al. (2004). Sleep-promoting properties of quetiapine in healthy subjects. Psychopharmacology (Berl), 174(3), 421–429.
Coogan, A. N., Schenk, M., Palm, D., Uzoni, A., Grube, J., Tsang, A. H., et al. (2019). Impact of adult attention deficit hyperactivity disorder and medication status on sleep/wake behavior and molecular circadian rhythms. Neuropsychopharmacology, 44(7), 1198–1206. PubMedPubMedCentralCrossRef
Cosci, F., & Chouinard, G. (2020). Acute and persistent withdrawal syndromes following discontinuation of psychotropic medications. Psychotherapy and Psychosomatics, 7, 1–24. CrossRef
Crochet, S., & Sakai, K. (1999). Alpha-2 adrenoceptor mediated paradoxical (REM) sleep inhibition in the cat. NeuroReport, 10(10), 2199–2204. PubMedCrossRef
Dallaspezia, S., & Benedetti, F. (2015). Chronobiology of bipolar disorder: Therapeutic implication. Current Psychiatry Reports, 17, 68. CrossRef
Darker, C. D., Sweeney, B. P., Barry, J. M., Farrell, M. F., & Donnelly-Swift, E. (2015). Psychosocial interventions for benzodiazepine harmful use, abuse or dependence. The Cochrane Database of Systematic Reviews, (5), CD009652.
Dassanayake, T., Michie, P., Carter, G., & Jones, A. (2011). Effects of benzodiazepines, antidepressants and opioids on driving: A systematic review and meta-analysis of epidemiological and experimental evidence. Drug Safety, 34(2), 125–156.
De Smidt, P. C., & Spaans, H. P. (2011). Serotoninesyndroom bij tranylcypromine en lage dosis trazodon; 5-ht2a, 5-ht1a, sert en selectiviteit. Psyfar, 3, 50–53.
Doghramji, K., & Jangro, W. C. (2016). Adverse effects of psychotropic medications on sleep. Sleep Medicine Clinics, 11(4), 503–514. PubMedCrossRef
Englisch, S., Jung, H. S., Lewien, A., et al. (2016). Agomelatine for the treatment of major depressive episodes in schizophrenia-spectrum disorders: An open-prospective proof-of-concept study. Journal of Clinical Psychopharmacology, 36, 597–607. PubMed
Everitt, H., Baldwin, D. S., Stuart, B., Lipinska, G., Mayers, A., Malizia, A. L., et al. (2018). Antidepressants for insomnia in adults. Cochrane Database of Systematic Reviews, 5. Art. No.: CD010753.
Faraone, S. V. (2018). The pharmacology of amphetamine and methylphenidate: Relevance to the neurobiology of attention-deficit/hyperactivity disorder and other psychiatric comorbidities. Neuroscience and Biobehavioral Reviews, 87, 255–270. PubMedCrossRefPubMedCentral
Fluyau, D., Revadigar, N., & Manobianco, B. E. (2018). Challenges of the pharmacological management of benzodiazepine withdrawal, dependence, and discontinuation. Therapeutic Advances in Psychopharmacology, 8(5), 147–168. PubMedPubMedCentralCrossRef
Fung, C. H., Martin, J. L., Alessi, C., Dzierzewski, J. M., Cook, I. A., Moore, A., et al. (2019). Hypnotic discontinuation using a blinded (masked) tapering approach: A case series. Front Psychiatry, 24(10), 717.
Geoffroy, P. A., Samalin, L., Llorca, P. M., Curis, E., & Bellivier, F. (2016). Influence of lithium on sleep and chronotypes in remitted patients with bipolar disorder. Journal of Affective Disorders, 204, 32–39. PubMedCrossRef
Glass, J., Lanctôt, K. L., Herrmann, N., Sproule, B. A., & Busto, U. E. (2005 Nov 19). Sedative hypnotics in older people with insomnia: Meta-analysis of risks and benefits. BMJ, 331(7526), 1169.
González, S., Moreno-Delgado, D., Moreno, E., Pérez-Capote, K., Franco, R., Mallol, J., et al. (2012). Circadian-related heteromerization of adrenergic and dopamine D 4 receptors modulates melatonin synthesis and release in the pineal gland. PLoS Biology, 10(6), e1001347. PubMedPubMedCentralCrossRef
Gould, R. L., Coulson, M. C., Patel, N., Highton-Williamson, E., & Howard, R. J. (2015). Interventions for reducing benzodiazepine use in older people: meta-analysis of randomised controlled trials. British Journal of Psychiatry, 204(2), 98–107. CrossRef
Hale, A., Corral, R.-M., Mencacci, C., et al. (2010). Superior antidepressant efficacy results of agomelatine versus fluoxetine in severe MDD patients: a randomized, double-blind study. International Clinical Psychopharmacology, 25, 305–314. PubMedCrossRef
Hassinger, A. B., Bletnisky, N., Dudekula, R., & El-Solh, A. A. (2020). Selecting a pharmacotherapy regimen for patients with chronic insomnia. Expert Opinion on Pharmacotherapy, 23, 1–9.
Hohagen, F., Rink, K., Käppler, C., Schramm, E., Riemann, D., Weyerer, S., et al. (1993). Prevalence and treatment of insomnia in general practice. A longitudinal study. European Archives of Psychiatry and Clinical Neuroscience, 242(6), 329–336.
Holsboer-Trachsler, E., & Prieto, R. (2013). Effects of pregabalin on sleep in generalized anxiety disorder. International Journal of Neuropsychopharmacology, 16(4), 925–936. CrossRefPubMed
Huynh, N., Lavigne, G. J., Lanfranchi, P. A., Montplaisir, J. Y., & De Champlain, J. (2006). The effect of 2 sympatholytic medications–propranolol and clonidine–on sleep bruxism: Experimental randomized controlled studies. Sleep, 29, 307–316. PubMedCrossRef
Jaffer, K. Y., Chang, T., Vanle, B., Dang, J., Steiner, A. J., Loera, N., et al. (2017). Trazodone for insomnia: A systematic review. Innovations in Clinical Neuroscience, 14(7–8), 24–34. PubMedPubMedCentral
Jain, S. V., & Glauser, T. A. (2014). Effects of epilepsy treatments on sleep architecture and daytime sleepiness: an evidence-based review of objective sleep metrics. Epilepsia, 55(1), 26–37. CrossRefPubMed
Kamphuis, J., Taxis, K., Schuiling-Veninga, C. C. M., Bruggeman, R., & Lancel, M. (2015). Off-label prescriptions of low-dose quetiapine and mirtazapine for insomnia in The Netherlands. Journal of Clinical Psychopharmacology, 35, 468–470. PubMed
Karsten, J., Hagenauw, L. A., Kamphuis, J., & Lancel, M. (2017). Low doses of mirtazapine or quetiapine for transient insomnia: A randomised, double-blind, cross-over, placebo-controlled trial. Journal of Psychopharmacology, 31(3), 327–337. PubMedCrossRef
Khachatryan, D., Groll, D., Booij, L., Sepehry, A. A., & Schütz, C. G. (2016). Prazosin for treating sleep disturbances in adults with posttraumatic stress disorder: A systematic review and meta-analysis of randomized controlled trials. General Hospital Psychiatry, 39, 46–52. PubMedCrossRef
Kim, S. W., Shin, I. S., Kim, J. M., Park, K. H., Youn, T., & Yoon, J. S. (2008). Factors potentiating the risk of mirtazapine-associated restless legs syndrome. Human Psychopharmacology, 23(7), 615–620. PubMedCrossRef
Kim, S. W., Shin, I. S., Kim, J. M., Yang, S. J., Shin, H. Y., & Yoon, J. S. (2005). Bupropion may improve restless legs syndrome: A report of three cases. Clinical Neuropharmacology, 28(6), 298–301. PubMedCrossRef
Kluge, M., Schüssler, P., & Steiger, A. (2007). Duloxetine increases stage 3 sleep and suppresses rapid eye movement (REM) sleep in patients with major depression. European Neuropsychopharmacology, 17, 527–531. PubMedCrossRef
Kolla, B. P., Mansukhani, M. P., & Bostwick, J. M. (2018). The influence of antidepressants on restless legs syndrome and periodic limb movements: A systematic review. Sleep Medicine Reviews, 38, 131–140. PubMedCrossRef
Kooy, A., Peters-Romeyn, B. M. T., & Van Gool, A. R. (1993). Mono-amino-oxydase-remmers: intoxicaties en interacties. Nederlands Tijdschrift voor Geneeskunde, 137(38), 1910–1914. PubMed
Kripke, D. F. (2015). Is suvorexant a better choice than alternative hypnotics? F1000Research, 4, 456.
Krystal, A. D. (2015). New developments in insomnia medications of relevance to mental health disorders. Psychiatric Clinics of North America, 38(4), 843–860. PubMedCrossRef
Lähteenmäki, R., Puustinen, J., Vahlberg, T., Lyles, A., Neuvonen, P. J., Partinen, M., et al. (2014). Melatonin for sedative withdrawal in older patients with primary insomnia: A randomized double-blind placebo-controlled trial. British Journal of Clinical Pharmacology, 77(6), 975–985. PubMedCrossRef
Lancel, M., & Karsten, J. (2013). Antidepressiva: Effecten op de slaap. Psyfar, 3, 20–26.
Lemoine, P., Guilleminault, C., & Alvarez, E. (2007). Improvement in subjective sleep in major depressive disorder with a novel antidepressant, agomelatine: randomized, double-blind comparison with venlafaxine. Journal of Clinical Psychiatry, 68, 1723–1732. PubMedCrossRef
Liguori, C., Ferini-Strambi, L., Izzi, F., et al. (2019). Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: A retrospective questionnaire analysis. British Journal of Clinical Pharmacology, 85(1), 240–244. PubMedCrossRef
Linden, M., & Thiels, C. (2001). Epidemiology of prescriptions for neuroleptic drugs: Tranquilizers rather than antipsychotics. Pharmacopsychiatry., 34(4), 150–154. PubMedCrossRef
Lo, H. S., Yang, C. M., Lo, H. G., Lee, C. Y., Ting, H., & Tzang, B. S. (2010). Treatment effects of gabapentin for primary insomnia. Clinical Neuropharmacology, 33(2), 84–90. PubMedCrossRef
Manconi, M., Ferri, R., Miano, S., Maestri, M., Bottasini, V., Zucconi, M., et al. (2017). Sleep architecture in insomniacs with severe benzodiazepine abuse. Clinical Neurophysiology, 128(6), 875–881. PubMedCrossRef
Marshall, N. S., Brendon, Y. J., Desai, A. V., et al. (2008). Two randomized placebo-controlled trials to evaluate the efficacy and tolerability of mirtazapine for the treatment of obstructive sleep apnea. Sleep, 31, 824–831. PubMedPubMedCentralCrossRef
Mason, M., Cates, C. J., & Smith, I. (2015). Effects of opioid, hypnotic and sedating medications on sleep-disordered breathing in adults with obstructive sleep apnoea. Cochrane Database of Systematic Reviews, 14(7), CD011090.
Mattila, T., Stoyanova, V., Elferink, A., Gispen-de Wied, C., De Boer, A., & Wohlfarth, T. (2011). Insomnia medication: do published studies reflect the complete picture of efficacy and safety? European Neuropsychopharmacology, 21(7), 500–507. PubMedCrossRef
Mayers, A. G., & Baldwin, D. S. (2005). Antidepressants and their effect on sleep. Human Psychopharmacology Clinical and Experimental, 20, 533–559. PubMedCrossRef
Mazza, M., Losurdo, A., Testani, E., et al. (2014). Polysomnographic findings in a cohort of chronic insomnia patients with benzodiazepine abuse. Journal of Clinical Sleep Medicine, 10(1), 35–42. PubMedPubMedCentralCrossRef
McGlashan, E. M., Nandam, L. S., Vidafar, P., et al. (2018). The SSRI citalopram increases the sensitivity of the human circadian system to light in an acute dose. Psychopharmacology (Berl), 235, 3201–3209. CrossRef
Menon, V., & Madhavapuri, P. (2017). Low-dose mirtazapine-induced nightmares necessitating its discontinuation in a young adult female. Journal of Pharmacology and Pharmacotherapeutics, 8, 182–184. PubMedCrossRefPubMedCentral
Mitchell, M. D., Gehrman, P., Perlis, M., & Umscheid, C. A. (2012). Comparative effectiveness of cognitive behavioral therapy for insomnia: A systematic review. BMC Family Practice, 25(13), 40. CrossRef
Miyazaki, S., Uchida, S., Mukai, J., & Nishihara, K. (2004). Clonidine effects on all-night human sleep: Opposite action of low- and medium-dose clonidine on human NREM–REM sleep proportion. Psychiatry and Clinical Neurosciences, 58(2), 138–144. PubMedCrossRef
Molemans Praktische Psychofarmacologie, 2015 geheel herziene editie, onder redactie van P. Naarding en E. Beers.
Monti, J. M., Alterwain, P., & Monti, D. (1990). The effects of moclobemide on nocturnal sleep of depressed patients. Journal of Affective Disorders, 20(3), 201–208. PubMedCrossRef
Monti, J. M., & Monti, D. (2000). Histamine H1 receptor antagonists in the treatment of insomnia. Molecular Diagnosis & Therapy, 13, 87–96.
Monti, J. M., Torterolo, P., & Pandi Perumal, S. R. (2017). The effects of second generation antipsychotic drugs on sleep variables in healthy subjects and patients with schizophrenia. Sleep Medicine Reviews, 33, 51–57. PubMedCrossRef
Morgenthaler, T. I., Auerbach, S., Casey, K. R., et al. (2018). Position paper for the treatment of nightmare disorder in adults: An American Academy of Sleep Medicine position paper. Journal of Clinical Sleep Medicine, 14(6), 1041–1055. PubMedPubMedCentralCrossRef
Morin, C. M., Vallières, A., Guay, B., Ivers, H., Savard, J., Mérette, C., et al. (2009). Cognitive behavioral therapy, singly and combined with medication, for persistent insomnia: A randomized controlled trial. JAMA, 301(19), 2005–2015. PubMedPubMedCentralCrossRef
Morrissette, D. A., & Stahl, S. M. (2014). CME Review article; modulating the serotonin system in the treatment of major depressive disorder. CNS Spectrums, 1–15.
Nagay, A. (2016). Clonidine use in psychiatry: Panacea or panache? Pharmacology, 98, 87–92. CrossRef
Nguyen, M., Tharani, S., Rahmani, M., & Shapiro, M. (2014). A review of the use of clonidine as a sleep aid in the child and adolescent population. Clinical Pediatrics, 53(3), 211–216. PubMedCrossRef
Nieuwhof, M. A. E. (2019). Off-labelgebruik mirtazapine als slaapmiddel. Geneesmiddelen Bulletin, 53, 66–68.
Nolen, W. A., Haffmans, P. M., Bouvy, P. F., & Duivenvoorden, H. J. (1993). Monoamine oxidase inhibitors in resistant major depression. A double-blind comparison of brofaromine and tranylcypromine in patients resistant to tricyclic antidepressants. Journal of Affective Disorders, 28, 189–197.
Odagaki, Y., Toyoshima, R., & Yamauchi, T. (2005). Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. Journal of Psychopharmacology, 19(3), 235–241. PubMedCrossRef
Ostadhadi, S., Khan, M. I., Norouzi-Javidan, A., Chamanar, M., Jazaeri, F., Zolfaghari, S., et al. (2016). Involvement of NMDA receptors and L-arginine/nitric oxide/cyclic guanosine monophosphate pathway in the antidepressant-like effects of topiramate in mice forced swimming test. Brain Research Bulletin, 122, 62–70. PubMedCrossRef
Ott, G. E., Rao, U., Lin, K. M., Gertsik, L., & Poland, R. E. (2004). Effect of treatment with bupropion on EEG sleep: Relationship to antidepressant response. International Journal of Neuropsychopharmacology, 7, 275–281. CrossRefPubMed
Palazidou, E., Papadopoulos, A., Sitsen, A., et al. (1989). An alpha2 adrenoceptor antagonist, Org 3770, enhances nocturnal melatonin secretion in man. Psychopharmacology (Berl), 97, 115–117. CrossRef
Page, R. L., Ruscin, J. M., Bainbridge, J. L., & Brieke, A. A. (2008). Restless legs syndrome induced by escitalopram: Case report and review of the literature. Pharmacotherapy, 28(2), 271–280. PubMedCrossRef
Parrino, L., & Terzano, M. G. (1996). Polysomnographic effects of hypnotic drugs. A review. Psychopharmacology (Berl), 126(1), 1–16. CrossRef
Parrino, L., Smerieri, A., Giglia, F., Milioli, G., De Paolis, F., & Terzano, M. G. (2008). Polysomnographic study of intermittent zolpidem treatment in primary sleep maintenance insomnia. Clinical Neuropharmacology, 31(1), 40–50. PubMedCrossRef
Patel, R., & Dickenson, A. H. (2016). Mechanisms of the gabapentinoids and α 2 δ-1 calcium channel subunit in neuropathic pain. Pharmacology Research and Perspectives, 4(2), e00205. PubMedCrossRefPubMedCentral
Peckham, A. M., Evoy, K. E., Ochs, L., & Covvey, J. R. (2018). Gabapentin for off-label use: Evidence-based or cause for concern? Subst Abuse, 12, 1178221818801311. PubMedPubMedCentral
Pillai, V., Cheng, P., Kalmbach, D. A., Roehrs, T., Roth, T., & Drake, C. L. (2016). Prevalence and predictors of prescription sleep aid use among individuals with DSM-5 insomnia: The role of hyperarousal. Sleep, 39(4), 825–832. PubMedPubMedCentralCrossRef
Pillai, V., Roth, T., Roehrs, T., Moss, K., Peterson, E. L., & Drake, C. L. (2017). Effectiveness of benzodiazepine receptor agonists in the treatment of insomnia: An examination of response and remission rates. Sleep, 40(2), zsw044.
Poyares, D., Guilleminault, C., Ohayon, M. M., & Tufik, S. (2004). Chronic benzodiazepine usage and withdrawal in insomnia patients. Journal of Psychiatric Research, 38(3), 327–334. PubMedCrossRef
Puustinen, J., Lähteenmäki, R., Polo-Kantola, P., Salo, P., Vahlberg, T., Lyles, A., et al. (2014). Effect of withdrawal from long-term use of temazepam, zopiclone or zolpidem as hypnotic agents on cognition in older adults. European Journal of Clinical Pharmacology, 70(3), 319–329. PubMedCrossRef
Qaseem, A., Kansagara, D., Forciea, M. A., Cooke, M., & Denberg, T. D. (2016). Management of chronic insomnia disorder in adults: A clinical practice guideline from the American College of Physicians. Annals of Internal Medicine, 165(2), 125–133. PubMedCrossRef
Quera-Salva, M.-A., Haja, G., Philip, P., et al. (2011). Comparison of agomelatine and escitalopram on nighttime sleep and daytime condition and efficacy in major depressive disorder patients. International Clinical Psychopharmacology, 26, 252–262. PubMedCrossRef
Rajan, R., & Syn, Y. M. (2017). Reevaluating antidepressant selection in patients with bruxism and temporomandibular joint disorder. Journal of Psychiatric Practice, 23, 173–179. PubMedCrossRef
Raskind, M. A., Peskind, E. R., Chow, B., et al. (2018). Trial of prazosin for post-traumatic stress disorder in military veterans. The New England Journal of Medicine, 378(6), 507–517. PubMedCrossRef
Richards, A., Inslicht, S., Ruoff, L. M., Metzler, T. J., Goldstein, L. A., Chapman, C. M., et al. (2018). An open-label study of doxazosin extended-release for PTSD: Findings and recommendations for future research on doxazosin. Focus (American Psychiatric Publishing), 16(1), 67–73.
Riemann, D., Baglioni, C., & Bassetti, C. (2017). European guideline for the diagnosis and treatment of insomnia. Journal of Sleep Research, 26(6), 675–700. PubMedCrossRef
Roth, T., Arnold, L. M., Garcia-Borreguero, D., Resnick, M., & Clair, A. G. (2014). A review of the effects of pegabalin on sleep disturbance across multiple clinical conditions. Sleep Medicine Reviews, 18(3): 261–271.
Rottach, K. G., Schaner, B. M., Kirch, M. H., Zivotofsky, A. Z., Teufel, L. M., & Gallwitz, T., et al. (2008). Restless legs syndrome as side effect of second generation antidepressants. Journal of Psychiatric Research, 43(1), 70–75.
Rudisill, T. M., Zhu, M., Kelley, G. A., Pilkerton, C., & Rudisill, B. R. (2016). Medication use and the risk of motor vehicle collisions among licensed drivers: A systematic review. Accident Analysis and Prevention, 96, 255–270. PubMedPubMedCentralCrossRef
Russel, I. J., Crofford, L. J., Leon, T., et al. (2009). The effects of pregabalin on sleep disturbance symptoms among individuals with fibromyalgia syndrome. Sleep Medicine, 10(6), 604–610. CrossRef
Salin-Pasqual, R. J., Herrera-Estrella, M., Galicia-Polo, L., et al. (1999). Olanzapine acute administration in schizophrenic patients increases delta sleep and sleep efficiency. Biological Psychiatry, 46(1), 141–143. CrossRef
Salminen, A. V., & Winkelmann, J. (2018). Restless legs syndrome and other movement disorders of sleep-treatment update. Current Treatment Options in Neurology, 20(12), 55. PubMedCrossRef
Salvi, V., Mencacci, C., & Barone-Adesi, F. (2016). H1-histamine receptor affinity predicts weight gain with antidepressants. European Neuropsychopharmacology, 26(10), 1673–1677. PubMedCrossRef
Sateia, M. J., Buysse, D. J., Krystal, A. D., Neubauer, D. N., & Heald, J. L. (2017). Clinical practice guideline for the pharmacologic treatment of chronic insomnia in adults: An American academy of sleep medicine clinical practice guideline. Journal of Clinical Sleep Medicine, 13(2), 307–349. PubMedPubMedCentralCrossRef
Schierenbeck, T., Riemann, D., Berger, M., & Hornyak, M. (2008). Effect of illicit recreational drugs upon sleep: cocaine, ecstasy and marijuana. Sleep Medicine Reviews, 12(5), 381–389.
Schifano, F., Chiappini, S., Corkery, J. M., & Guirguis, A. (2019). An insight into Z-drug abuse and dependence: An examination of reports to the European medicines agency database of suspected adverse drug reactions. International Journal of Neuropsychopharmacology, 22(4), 270–277. PubMedCentralCrossRefPubMed
Schittecatte, M., Dumont, F., Machowski, R., et al. (2002). Effects of mirtazapine on sleep polygraphic variables in major depression. Neuropsychobiology, 46, 197–201. PubMedCrossRef
Schmid, D. A., Wichniak, A., Uhr, M., et al. (2006). Changes of sleep archictecture, spectral composition of sleep EEG, the nocturnal secretion of cortisol, ACTH, GH, prolactin, melatonin, ghrelin, and leptin, and the DEX-CRH test in depressed patients during treatment with mirtazapine. Neuropsychopharmacology, 31, 832–844. PubMedCrossRef
Schonmann, Y., Goren, O., Bareket, R., Comaneshter, D., Cohen, A. D., & Vinker, S. (2018). Chronic hypnotic use at 10 years-does the brand matter? European Journal of Clinical Pharmacology, 74(12), 1623–1631. PubMedCrossRef
Schreiber, S., & Pick, C. G. (2020). Trazodone and mirtazapine: A possible opioid involvement in their use (at low dose) for sleep? Medical Hypotheses, 136, 190501. CrossRef
Schweitzer, P. K., & Feren, S. D. (2017). Pharmacological Treatment of Insomnia. In H. Attarian (red.), Clinical handbook of insomnia. Current clinical neurology. Springer: Cham.
Seeman, D. (2014). Clozapine, a fast-off-D2 antipsychotic. ACS Chemical Neuroscience, 5(1), 24–29. PubMedCrossRef
Shen, J., Chung, S. A., Kayumov, L., et al. (2006). Polysomnographic and symptomatological analyses of major depressive disorder patients treated with mirtazapine. Canadian Journal of Psychiatry, 51, 27–34. PubMedCrossRef
Shuman, M., Chukwu, A., Van Veldhuizen, N., & Miller, S. A. (2019). Relationship between mirtazapine dose and incidence of adrenergic side effects: An exploratory analysis. Mental Health Clinician, 9, 41–47. PubMedCrossRefPubMedCentral
Sivertsen, B., Omvik, S., Pallesen, S., Nordhus, I. H., & Bjorvatn, B. (2009). Sleep and sleep disorders in chronic users of zopiclone and drug-free insomniacs. Journal of Clinical Sleep Medicine, 5(4), 349–354. PubMedPubMedCentralCrossRef
Smith, C., & Koola, M. M. (2016). Evidence for using doxazosin in the treatment of posttraumatic stress disorder. Psychiatric Annals, 46(9), 553–555. PubMedPubMedCentralCrossRef
Stahl, S. (2009). Stahl’s essential psychopharmacology. The prescriber’s guide. Derde editie. Verenigd Koninkrijk: Cambridge University Press.
Stahl, S., & Morrissette, D. A. (2016). Stahl’s illustrated sleep and wake disorders. Verenigd Koninkrijk: Cambridge University Press.
Stein, D. J., Ahokas, A. A., & De Bodinat, C. (2008). Efficacy of agomelatine in generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. Journal of Clinical Psychopharmacology, 28, 561–566. PubMedCrossRef
Storebø, O. J., Pedersen, N., Ramstad, E., et al. (2018). Methylphenidate for attention deficit hyperactivity disorder (ADHD) in children and adolescents – assessment of adverse events in non-randomized studies. Cochrane Database of Systematic Reviews, 9(5), CD012069.
Sun, H., Kennedy, W. P., Wilbraham, D., Lewis, N., Calder, N., Li, X., et al. (2013). Effects of suvorexant, an orexin receptor antagonist, on sleep parameters as measured by polysomnography in healthy men. Sleep, 36(2), 259–267. PubMedPubMedCentral
Takaesu, Y., Komada, Y., Asaoka, S., Kagimura, T., & Inoue, Y. (2014 Nov 19). Factors associated with long-term use of hypnotics among patients with chronic insomnia. PLoS One, 9(11), e113753.
Takaesu, Y., Utsumi, T., Okajima, I., et al. (2019). Psychosocial intervention for discontinuing benzodiazepine hypnotics in patients with chronic insomnia: A systematic review and meta-analysis. Sleep Medicine Reviews, 48, 101214. PubMedCrossRef
Tan, L., Zhou, J., Yang, L., Ren, R., Zhang, Y., Li, T., et al. (2017). Duloxetine-induced rapid eye movement sleep behavior disorder: A case report. BMC Psychiatry, 17(1), 372. PubMedPubMedCentralCrossRef
Taylor, F. B., Martin, P., Thomposon, C., et al. (2008). Prazosin effects on objective sleep measures and clinical symptoms in civilian trauma PTSD: A placebo-controlled study. Biological Psychiatry, 63(6), 629–632.
Taylor, H. L., Rybarczyk, B. D., Nay, W., & Leszczyszyn, D. (2015). Effectiveness of a CBT intervention for persistent insomnia and hypnotic dependency in an outpatient psychiatry clinic. Journal of Clinical Psychology, 71(7), 666–683. PubMedCrossRef
Thompson, W., Quay, T. A. W., Rojas-Fernandez, C., et al. (2016). Atypical antipsychotics for insomnia: A systematic review. Sleep Medicine, 22, 13–17. PubMedCrossRef
Thorpy, M. J., & Bogan, R. K. (2020). Update on the pharmacologic management of narcolepsy: Mechanisms of action and clinical implications. Sleep Medicine, 68, 97–109. PubMedCrossRef
Trenkwalder, C., Allen, R., Högl, B., Clemens, S., Patton, S., Schormair, B., et al. (2018). Comorbidities, treatment, and pathophysiology in restless legs syndrome. Lancet Neurology, 17(11), 994–1005. PubMedCrossRef
Tribl, G. G., Wetter, T. C., & Schredl, M. (2013). Dreaming under antidepressants: A systematic review on evidence in depressive patients and healthy volunteers. Sleep Medicine Reviews, 17(2), 133–142. PubMedCrossRef
Uca, A. U., Uğuz, F., Kozak, H. H., et al. (2015). Antidepressant-induced sleep bruxism: Prevalence, incidence, and related factors. Clinical Neuropharmacology, 38, 227–230.
Uchiyama, M., Sakamoto, S., & Miyata, L. (2019). Effect of ramelteon on insomnia severity: Evaluation of patient characteristics affecting treatment response. Sleep and Biological Rhythms, 17, 379–388. CrossRef
Vande Griend, J. P., Anderson, S. L. (2012). Histamine-1 receptor antagonism for treatment of insomnia. Journal of the American Pharmacists Association, 52(6), e210–e219.
Vermeeren, A., Wolschrijn, H., Leufkens, T. R. M., Theunissen, E. L., Kuypers, K. P. C., & Ramaekers, J. G. (2010). Psychofarmaca en rijvaardigheid. Psyfar, 2, 62–65.
Vermetten, E. (2017). Stand van zaken van de farmacotherapie voor PTSS, deel I: Overzicht en update. Psyfar, 2, 18–26.
Vicens, C., Sempere, E., Bejarano, F., et al. (2016). Efficacy of two interventions on the discontinuation of benzodiazepines in long-term users: 36-month follow-up of a cluster randomised trial in primary care. British Journal of General Practice, 66(643), e85–e91.
Vickers-Smith, R., Sun, J., Charnigo, R. J., Lofwall, M. R., Walsh, S. L., & Havens, J. R. (2020). Gabapentin drug misuse signals: A pharmacovigilance assessment using the FDA adverse event reporting system. Drug and Alcohol Dependence, 1(206), 107709. CrossRef
Wade, A. G., Ford, I., Crawford, G., et al. (2010). Nightly treatment of primary insomnia with prolonged release melatonin for 6 months: a randomized placebo controlled trial on age and endogenous melatonin as predictors of efficacy and safety. BMC Medicine, 8, 51. PubMedPubMedCentralCrossRef
Walsh, J. K., Erman, M., Erwin, C. W., et al. (1998). Subjective hypnotic efficacy of trazodone and zolpidem in DSMIII-R primary insomnia. Human Psychopharmacology, 13(3), 191–198. CrossRef
Weber, J., Siddiqui, M. A. A., Wagstaff, A. J., et al. (2010). Low-Dose Doxepin. CNS Drugs, 24, 713–720. PubMedCrossRef
Williams, R. R., & Sandigo, G. (2017). Venlafaxine-induced REM sleep behavioral disorder presenting as two fractures. Trauma Case Reports, 11, 18–19. CrossRef
Wilson, S., & Argyropoulos, S. (2005). Antidepressants and Sleep. CNS Drugs, 65, 927–947. CrossRef
Wilson, S. J., Bailey, J. E., & Rich, A. S. (2005). The use of sleep measures to compare a new 5HT1A agonist with buspirone in humans. Journal of Psychopharmacology, 19, 609–613. PubMedCrossRef
Wilson, S., Højer, A. M., Buchberg, J., Areberg, J., & Nutt, D. J. (2015). Differentiated effects of the multimodal antidepressant vortioxetine on sleep architecture: Part 1, a pharmacokinetic/pharmacodynamic comparison with paroxetine in healthy men. Journal of Psychopharmacology, 29(10), 1085–1091. PubMedCrossRef
Winokur, A., Gary, K. A., Rodner, S., Rae-Red, C., Fernando, A. T., & Szuba, M. P. (2001). Depression, sleep physiology, and antidepressant drugs. Depression and Anxiety, 14, 19–28. PubMedCrossRef
Wong, C. K., Marshall, N. S., Grunstein, R. R., Ho, S. S., Fois, R. A., Hibbs, D. E., et al. (2017 Feb 15). Spontaneous adverse event reports associated with zolpidem in the United States 2003–2012. Journal of Clinical Sleep Medicine, 13(2), 223–234.
Wright, A., Diebold, J., Otal, J., Stoneman, C., Wong, J., Wallace, C., et al. (2015). The effect of melatonin on benzodiazepine discontinuation and sleep quality in adults attempting to discontinue benzodiazepines: A systematic review and meta-analysis. Drugs and Aging, 32(12), 1009–1018. PubMedCrossRef
Wynchank, D., Bijlenga, D., Beekman, A. T., Kooij, J. J. S., Penninx, B. W. (2017 Oct 30). Adult attention-deficit/hyperactivity disorder (ADHD) and insomnia: An update of the literature. Current Psychiatry Reports, 19(12), 98.
Yamada, Y., Shibuya, F., Hamada, J., Sawada, Y., & Iga, T. (1995). Prediction of sleep disorders induced by beta-adrenergic receptor blocking agents based on receptor occupancy. Journal of Pharmacokinetics and Biopharmaceutics, 23(2), 131–145. PubMedCrossRef
Yeh, M. S., Mari, J. J., Costa, M. C., Andreoli, S. B., Bressan, R. A., & Mello, M. F. (2011). A Double-Blind Randomized Controlled Trial To Study the Efficacy of Topiramate in a Civilian Sample of PTSD. CNS Neuroscience & Therapeutics, 17(5), 305–310. CrossRef
Zapp, A. A., Fischer, E., & Deuschle, M. (2017). The effect of agomelatine and melatonin on sleep-related eating: A case report. Journal of Medical Case Reports, 11, 275. PubMedPubMedCentralCrossRef
Metagegevens
Titel
Psychofarmaca en de behandeling van slaapstoornissen
Auteurs
drs. Maaike van Veen
dr. Jeanine Kamphuis
dr. Rixt Riemersma-van der Lek
Copyright
2021
Uitgeverij
Bohn Stafleu van Loghum
Boek
Slaapstoornissen in de psychiatrie

Print ISBN: 978-90-368-2523-8

Elektronisch ISBN: 978-90-368-2524-5

Copyright: 2021

DOI
https://doi.org/10.1007/978-90-368-2524-5_19